Neoadjuvant immunotherapy has emerged as a promising approach in the treatment of
various malignancies, with preclinical studies showing improved immune responses in the …

Background Immune checkpoint inhibitors (ICI) have become first-line treatment for
metastatic colorectal cancer (CRC) with deficient mismatch repair (dMMR). Despite the …

Objective Examine patients with locally advanced rectal cancer (LARC) with deficient
mismatch repair (dMMR) or microsatellite instability-high (MSI-H) who received neoadjuvant …

Despite therapeutic advancements, disease-free survival and overall survival of patients
with locally advanced rectal cancer have not improved in most trials as a result of distant …

Molecular testing is an essential component of the pathologic evaluation of colorectal
carcinoma providing diagnostic, prognostic, and predictive therapeutic information …

The development of deep learning (DL) models to predict the consensus molecular
subtypes (CMS) from histopathology images (imCMS) is a promising and cost-effective …

Purpose: Colorectal medullary carcinoma is extensive lymphocyte infiltration and associated
with an active immune response. However, studies to comprehensively explore the immune …

The multimodal approach with total mesorectal excision preceded by neoadjuvant (chemo)
radiotherapy represented the mainstay treatment for locally advanced rectal cancer (LARC) …

Simple Summary Locally advanced rectal cancer (LARC) is a group of highly
heterogeneous tumors. According to the European Society for Medical Oncology (ESMO) …

Simple Summary Immunotherapy is an innovative treatment that is highly effective against
certain cancers, such as skin and lung cancer. However, for colorectal cancer, one of the …